Browse the evidence

Genetic variation in the GLP1R locus is associated with cardiometabolic traits (BMI, blood pressure, type 2 diabetes) across diverse ancestries, but these variants do not influence GLP1R gene expression in a way that explains mental ill-health (MIH) endophenotypes.

If you are taking or considering GLP-1 receptor agonists (like semaglutide or tirzepatide) for weight loss or diabetes, be aware that any mental health benefits you experience are likely not due to the drug acting directly on your GLP-1 receptors. Genetic evidence suggests these behavioral effects operate through different mechanisms, possibly involving other genes or secondary metabolic improvements.

Elevated plasma levels of GDF15 and its receptors (RET and GFRAL) mediate the causal relationship between smoking intensity and reduced adiposity (lower BMI and body fat percentage).

Smoking suppresses weight partly through the GDF15 protein pathway. When people quit, this pathway downregulates, potentially leading to weight gain. Future treatments might target GDF15 (e.g., using drugs like metformin to boost it) to help people quit without gaining weight, rather than relying solely on nicotine replacement.

Genetically proxied exposure to GLP-1 receptor agonists is associated with a significantly reduced risk of Obstructive Sleep Apnea (OSA).

If you have OSA and obesity, GLP-1 agonists (like semaglutide or liraglutide) may help reduce your OSA risk by addressing underlying metabolic factors. This is supported by genetic evidence, but clinical trials are still needed to confirm efficacy in diverse populations. Consult your doctor to see if this is a suitable adjunct to your current OSA treatment.

Leptin acts as a critical signal linking nutritional status to puberty onset and reproductive function in females, with sufficient levels required to activate hypothalamic pathways for ovulation.

For females, maintaining healthy body fat levels is crucial for the onset of puberty and regular ovulation. Leptin, a hormone from fat cells, signals the brain that energy reserves are sufficient for reproduction. Extreme leanness can delay puberty or cause infertility, which may be reversible with leptin treatment.

Initiation of GLP-1 receptor agonists is associated with a small but statistically significant increased risk of acute pancreatitis, particularly during the first 6 months of treatment.

Be aware that GLP-1 RAs carry a small increased risk of acute pancreatitis, especially in the first 6 months. If you have a history of pancreatitis, discuss this carefully with your doctor. Report severe, persistent abdominal pain to your provider immediately, as it could be a sign of pancreatitis.

SGLT2 inhibitors lower blood pressure primarily through early osmotic diuresis and volume contraction, with sustained effects driven by reduced arterial stiffness and improved endothelial function.

If you have heart failure or diabetes, SGLT2 inhibitors (like Jardiance or Farxiga) will likely lower your blood pressure slightly, but this is a bonus, not the main reason for taking them. The benefit comes from reducing fluid volume and improving artery health, not just sugar control.

GLP-1 receptor agonist treatment alone, despite causing significant weight loss, does not improve physical functional performance or cardiorespiratory fitness compared to placebo.

Taking GLP-1 medication will help you lose weight, but it will not make you more physically fit or improve your ability to perform daily tasks. If you rely solely on medication, you may lose weight but not gain the stamina or functional strength that exercise provides. To improve fitness, you must add structured exercise.

GLP-1 and dual GLP-1/GIP receptor agonists cause predictable, dose-dependent gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation) that are generally mild to moderate and transient, though they significantly impact treatment adherence.

Expect digestive side effects like nausea or constipation when starting GLP-1 medications. These are common, usually mild, and tend to improve as your body adjusts. To minimize them, start with the lowest dose and increase slowly as directed by your doctor. Staying hydrated and eating smaller meals can help manage symptoms.

Epigenetic silencing of the GLP-1 receptor (GLP-1R) via DNMT3A-mediated hypermethylation impairs incretin signaling and insulin secretion in pancreatic beta-cells.

In Type 2 Diabetes, the body's ability to respond to GLP-1 (a hormone that stimulates insulin) is often turned off by epigenetic silencing of the GLP-1 receptor. This silencing is driven by enzymes like DNMT3A. Understanding this mechanism highlights why therapies that target these epigenetic modifiers or mimic GLP-1 (like GLP-1 agonists) are effective, as they bypass or reverse this specific block in insulin secretion.

Classical anti-obesity agents (orlistat, phentermine-topiramate, naltrexone-bupropion) typically achieve only modest weight loss (3-10%) and are limited by tolerability and safety concerns.

Orlistat is an older, oral weight loss medication that helps block fat absorption. It typically leads to modest weight loss (3-5%) and can cause gastrointestinal side effects like oily stools. It is generally reserved for patients who cannot access or tolerate newer, more effective injectable therapies.

Multi-agonist therapies (GLP-1/GIP, GLP-1/Glucagon, GLP-1/GIP/Glucagon) do not inherently offer better tolerability than GLP-1 monotherapy; in fact, glucagon receptor activation may increase nausea and vomiting rates.

Do not assume that newer, multi-agonist weight loss drugs are easier on your stomach than older GLP-1 drugs. Some of these newer drugs actually cause more nausea because they target additional receptors that can trigger vomiting. You still need to start with a low dose and go slow, regardless of how many receptors the drug targets.

Combination therapy with ARNIs and SGLT2 inhibitors produces synergistic cardiovascular, metabolic, and renal benefits in cardiometabolic syndrome (CMS) patients, though implementation is hindered by hypotension risks and cost.

If you have cardiometabolic syndrome, current guidelines suggest combining an ARNI (like sacubitril/valsartan) with an SGLT2 inhibitor (like empagliflozin or dapagliflozin) for the best heart, kidney, and metabolic protection. Start with low doses and increase slowly to avoid dizziness or low blood pressure. Monitor your kidney function and electrolytes regularly. Discuss insurance coverage with your provider, as these drugs can be expensive but are cost-effective long-term by preventing hospitalizations.

Novel mineralocorticoid receptor antagonists (MRAs) like finerenone reduce cardiovascular events and slow CKD progression in CMS patients with lower hyperkalemia risk compared to traditional MRAs.

If you have kidney disease and heart issues, ask your doctor about finerenone. It protects your kidneys and heart with a lower risk of dangerous potassium levels compared to older drugs. It is taken once daily.

Genetically proxied GIPR agonist reduces the risk of 14 cardiometabolic diseases, including obesity, hypertension, and coronary heart disease, with effects on angina and myocardial infarction partially mediated by the inflammatory biomarker Flt3L.

Genetic evidence supports that activating the GIP receptor reduces the risk of major cardiometabolic diseases, including obesity, hypertension, and heart conditions. This benefit is partly achieved by lowering levels of the inflammatory protein Flt3L, which is linked to angina and heart attacks. This suggests GIP-targeting therapies could offer broader heart health benefits beyond blood sugar control.

Endogenous GLP-1 and GIP hormones play a critical role in cardiovascular physiology, with GLP-1 promoting cardioprotection through anti-apoptotic signaling and improved glucose utilization, while GIP's role is complex and species-dependent.

Your body naturally produces hormones called GLP-1 and GIP that help protect your heart and blood vessels. GLP-1 improves blood flow, reduces inflammation, and helps your heart use energy efficiently during stress. GIP also plays a role in metabolism and heart health. Understanding these natural pathways helps explain why medications that mimic them are so effective for heart health.

Tirzepatide (0.144 mg/kg) significantly reduces voluntary alcohol consumption, prevents binge-like drinking, and suppresses relapse-like behaviors in rodents.

Tirzepatide, a dual GLP-1/GIP agonist, significantly reduces alcohol consumption and prevents relapse in rodent models by attenuating dopamine reward signaling. While preclinical, these findings suggest potential for treating Alcohol Use Disorder (AUD) and its metabolic complications.

Tirzepatide (5, 10, and 15 mg weekly) improves metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis in patients with biopsy-confirmed MASH and stage F2 or F3 fibrosis.

If you have moderate to severe fatty liver disease (MASH) with scarring (fibrosis), tirzepatide (5-15 mg weekly) can help resolve the liver inflammation and scarring in about 62% of patients at the highest dose, without making the scarring worse.

Leptin resistance is a common trait in obesity that impairs the feedback between fat mass and the hypothalamus, leading to dysregulated appetite and energy storage.

In obesity, the hormone leptin, which signals satiety, often stops working effectively (leptin resistance). This means the brain doesn't receive the 'stop eating' signal even when fat stores are high, contributing to continued overeating.

Short-term intensive insulin therapy (SIIT) using continuous subcutaneous insulin infusion or multiple daily injections for 2-3 weeks can induce sustained drug-free remission in newly diagnosed type 2 diabetes patients by restoring beta-cell function and reducing glucotoxicity.

If you were recently diagnosed with high blood sugar, ask your doctor about a short course of intensive insulin therapy (2-3 weeks). This 'reset' can restore your body's ability to manage blood sugar on its own, potentially allowing you to avoid lifelong medication.

Tirzepatide exposure does not significantly increase or decrease the risk of adverse cardiovascular events (myocardial infarction, coronary artery disease, heart failure, stroke) or adverse renal events (urinary tract infections, kidney stones, renal impairment, renal cell carcinoma) in participants with type 2 diabetes or obesity compared to control groups.

For patients with T2DM or obesity, current evidence from multiple randomized trials indicates that tirzepatide does not significantly increase or decrease the risk of major cardiovascular events (like heart attack or stroke) or specific renal adverse events (like kidney stones or UTIs) compared to other treatments or placebo. While long-term safety in high-risk groups requires more data, short-to-medium term use appears safe regarding these specific outcomes.

GLP-1 receptor agonists (GLP-1RAs) such as liraglutide and semaglutide reduce adipocyte size and promote the browning of white adipose tissue (WAT) by upregulating thermogenic genes (e.g., UCP1) and activating the AMPK/SIRT1 pathway, thereby shifting adipose tissue function from energy storage to energy expenditure.

If you are taking a GLP-1 medication like semaglutide or liraglutide, understand that it is actively remodeling your fat tissue. It shrinks fat cells and activates 'browning' processes that burn energy, which is a key part of why these drugs are effective for long-term metabolic health, beyond just reducing your appetite.

Combining tirzepatide with leptin produces synergistic weight loss and improved metabolic homeostasis in diet-induced obesity models, driven by reduced food intake and increased energy expenditure.

For individuals with obesity who have leptin resistance, adding leptin to tirzepatide treatment may enhance weight loss and metabolic health beyond what tirzepatide achieves alone. This synergy works by reducing food intake and increasing energy expenditure, suggesting that combination therapies targeting multiple hormonal pathways can overcome resistance mechanisms.

GLP-1 receptor agonist therapy is associated with significant gastrointestinal adverse events and weight regain upon discontinuation, limiting its long-term durability compared to surgery.

GLP-1 medications like semaglutide or liraglutide can help you lose 15-25% of your body weight, but you may experience nausea, vomiting, or digestive issues. Crucially, if you stop taking the medication, you are likely to regain the weight. Surgery offers more sustained weight loss and cardiovascular protection, though it involves surgical risks.

Resmetirom (THR-β agonist) improves biopsy-confirmed MASH resolution and fibrosis without causing significant weight loss, acting through a lipid-centric mechanism.

If you have MASH, resmetirom is a daily pill that targets liver fat and inflammation directly. It works even if you don't lose weight, making it a distinct option from weight-loss drugs.